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Polycarbophil (PCP), a kind of pharmaceutical polymers with superior bioadhesive prop-
erties has been widely used in the field of controlled drug delivery systems. It could be used
as a highly efficient thickener, bioadhesive agent, suspending aid and emulsion stabilizer
when dispersed in water or other polar solvents. These exceptional utilities of the poly-
mers result from their hydrophilic nature. Hydrogen bonding plays an important role in
most adhesion behaviours and becomes the main adhesion force. This paper reviews the
applications of PCP in pharmacy over the past decades, and clarifies its unique advantages
in the bioadhesive formulations. After an introduction discussing its structural charac-
teristics and action mechanism, the focus turned to the description of its available appli-
cations in detail with particular emphasis on the ocular, nasal, vagina and oral drug
delivery systems. The other less developed formulations are also described, including the
buccal and the transdermal delivery systems.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction These numerous theories should be regarded as complementsCurrently, the bioadhesive drug delivery system (BDDS) has
got much attention, and a great progress has been made by
researchers [1e3]. John D. Smart [4] and Sharma et al [5]
had discussed the mechanisms of mucoadhesion in detail,
including electronic theory, wetting theory, adsorption the-
ory, diffusion theory, mechanical theory and fracture theory.tical University, No. 103
305.
g).
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ang Pharmaceutical Univin the different stages of the mucus/substrate interaction,
rather than individual and absolute theory.
The wetting theory is mainly applicable to liquid or low
viscosity bioadhesive systems and is essentially a measure of
spread-ability of the drug crossing the biological substrate
[6]. The electronic theory describes adhesion characteristic
depending on electron transfer between the mucoadhesive, Wenhua Road, Shenyang 110016, China. Tel.: þ86 24 23986305,
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their electronic structures. The electron transfer causes the
formation of a double layer of electrical charges at the inter-
face of mucus and mucoadhesive, as well as produces the
attractive forces within this double layer [7]. According to the
fracture theory, the adhesive bond is related to the force of
separating the two surfaces between systems. This theory
relates the force for polymer detachment from themucus. The
work fracture will increase when the polymer network chains
are longer or the degree of cross-linking is low [6]. The
diffusion-interlocking theory proposes a time-dependent
diffusion between mucoadhesive polymer chains and the
glycoprotein chains of the mucus layer. This is a two-way
diffusion process, the permeability of the polymers depends
on the diffusion coefficients of the interacting polymers. And
the main factors affecting the diffusion process are the mo-
lecular weight (MW), cross-linking density, chain mobility/
flexibility and scalability of both networks [8]. It has been re-
ported that longer polymer chains can diffuse, interpenetrate
and entangle to the surface mucus, and the critical MW to
obtain interpenetration is at least 100,000 Dalton (Da).
Furthermore, excessive chain cross-linking will decrease the
polymer mobility and interfacial penetration [9].
In the adsorption theory, adhesion is defined as the result
of various surface interactions (primary and secondary
bonding) between the mucus substrate and adhesive poly-
mers. The primary bonding is produced by ionic, covalent and
metallic bonding, which is generally considered undesirable
due to their permanency. And the secondary bonding is arised
mainly due to hydrogen bonding, hydrophobic interactions
and van-der-Waals forces. Meanwhile because these in-
teractions require less energy to ‘break’, the secondary
bonding has become the most prominent form of surface
interaction in mucoadhesion processes as it has the advan-
tage of being semi-permanent bonding [6,10].
As is known to all, polymer properties can affect
mucoadhesion. According to the adhesion theory, the
different molecular structures and functional groups have a
great influence on the polymer/mucus interaction. As the
attachment and bonding of bioadhesive polymers to biological
organisms occurs mainly through interpenetration followed
by secondary bonding. And the secondary bonding is mainly
aroused by hydrogen bonding which is well accepted that
polymers possessing hydrophilic functional groups such as,
carboxyl (COOH), hydroxyl (OH), sulphate groups (SO4H)
and amide (NH2) may be more appropriate for formulating
targeted drug delivery platforms. Typically, secondary in-
teractions (mainly refers to hydrogen bonding) play a signifi-
cant role on the formation of stronger network. Therefore
polymers containing a high density of available hydrogen
bonding groups could combine withmucinmore strongly [11].
The hydration degree of polymers is another important factor
affecting themucoadhesive strength. Generally the higher the
degree of hydration, stronger the biological adhesion. How-
ever, excess hydration may cause a decline in mucoadhesion
because of the formation of a slippery mucilage. So polymers
with stronger hydration ability are more conductive to play
biological adhesion. The higher degree of cross-linking allows
greater control of drug release as well as increases the surface
area for polymer/mucus interpenetration.PCP is a high-molecular-weight acrylic acid polymer cross-
linked with polyalkenyl ethers or divinylglycol. There is a
large number of carboxyl (COOH) on the molecular chain. As a
pharmaceutical excipient, PCP is generally considered safe
and does not produce allergies and irritation to the skin [12]. It
is insoluble in aqueous media but in the neutral pH condi-
tions, it has a high swelling capacity and the volume can be
increased to 100 times, allowing high levels of entanglement
within the mucus layer. Comprehensive adhesion and the
inherent characteristics of PCP, the bioadhesive effect is pro-
duced by the carboxylic acid groups binding to the mucosal
surfaces via hydrogen bonding interaction [9]. As shown in
Fig. 1, the structures of PCP before and after swelling or
neutralizing are different in a suitable medium. In the non-
swollen state, the macromolecules are tightly coiled, so the
volume and viscosity are very small.When dispersed inwater,
the molecules will hydrate and uncoil to some extent, though
the molecular chains don’t achieve the greatest degree of
expansion, the viscosity of the system could be improved to a
greater extent. The performance of polymers will be maxi-
mized when they are fully uncoiled and extended, which can
be accomplished by neutralization or hydrogen bonding. The
hydrogen bonding force makes the viscosity increased
significantly. Fig. 2 depicts the detail of the hydrogen bonding
process and action principle of PCP from the perspective of
atomic three-dimensional structure. Furthermore, the gel is
formed in such platforms, which is caused by the electrostatic
repulsion between anionic groups [13].
The environmental pH value and ionic strength have a
strong impact on the viscosity of PCP [14]. As a pH-sensitive
gel, the carboxyl groups in molecular chains are neutralized
by adding the neutralizer (alkali, etc.). Negative chargeswill be
produced on the backbone of the molecular chains after the
polymers ionized by the neutralizer, which may turn the
molecules into an extended state with the repulsions of ho-
mogeneous charges. This reaction occurs rapidly and leads to
thickening effect, therefore it plays a strong role in viscosity.
Adjusting its pH value to 5 or above after the PCP dispersed in
the water with the concentration of 0.2%, the system would
turn into a gel immediately. But when a large number of ions
presented in the solution system, the concentration of the
polymer should be increased significantly to make it to a gel.
Studies showed that when the concentration of ions in the
solution reached 0.1 mol/l, the system would not convert to a
gel, even the concentration of PCP was up to 0.7%. So when
PCP is used as a gel matrix or a bioadhesive agent, the re-
searchers must pay special attention to the concentration of
the ions in the system, especially the divalent or trivalent
cationic. The mechanism of this phenomenon is the combi-
nation of dissimilar charges. In the highly dispersed systems
of PCP, there are many carboxyl negative charges exposing on
the extended molecular chain, making cations associated
which reduces the repulsion effect of the same charges,
leading the system lower degree of stretching, therefore the
viscosity is decreased. As a consequence, PCP is very sensitive
to the pH and ionic concentration in the host system, special
attention must be paid in this aspect.
Tang Xing et al [15] compared a series of bioadhesive
polymer materials, and found PCP has the highest values for
various properties such as swelling, humidification, viscosity
Fig. 1 e Schematic depicting the structure of PCP before and after swelling or neutralizing.
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following sequence by their comparison: PCP > Xanthan
gum> Carbopol 1342P> Carbopol 974P> Chitosan> Carbopol
971P > hydroxypropylmethyl-cellulose (Methacel K100M) >
CMC-Na > hydroxypropylmethyl-cellulose (Methacel K15M) >
gelatin > Acacia gum.
Many studies have showed that the carboxylic acid groups
can bind to the mucins by hydrogen bonding, in other words,
mucoadhesion is based on non-covalent bonds or entangle-
ment between mucus and polymers [9,16,17]. When the drug
containing PCP contacts with mucosal tissue, hydrogen
bonding makes the carrier and mucus adsorption occur. At
present, there is not any systematic biological adhesivity
theory. In view of the good bioadhesive properties of PCP, a
large number of studies have been conducted on drug delivery
systems. It has been proved that bioadhesive agents can be
adhered to the target sites in order to extend the retentionFig. 2 e Schematic depicting hydrtime of the drug in the lesion, and improve the treatment ef-
fect of local disease. Higher local drug concentration and the
close contact with the site of absorption can not only promote
absorption of the drug, but also increase concentration
gradient. Meanwhile, PCP modulates transport pathways by
opening epithelial tight junctions to promote the drug diffu-
sion. In addition, the drug adheres to the mucosa directly and
is absorbed by the mucosal capillaries to avoid the first-pass
effect of the liver, thereby to increase the bioavailability [18].
Furthermore, the use of bioadhesive slow (control) release
formulations can reduce the frequency of administration, and
thus improve patients’ compliance.
This paper reviews the usage of PCP as a carrier of
controlled release preparations in recent years, and focuses
on the different routes of administration. The development
and application of new formulations aim to provide new ideas
for BDDS.ogen bonding process of PCP.
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administration systems
2.1. In the ocular drug delivery systems
The traditional ocular preparations are usually lost quickly
from eyes by flowing away with tears, and gelatinous eye
preparations are easy to cover the surface of the cornea
resulting in blurred vision. Therefore, the current study fo-
cuses on selecting the appropriate bioadhesive materials to
extend residence time in the eyes. Although there are many
applications of carbomer in ocular formulations, carbomer is
usually used as a promoting agent rather than an adhesion
agent. PCP used in ocular drug delivery system has many su-
perior characteristics, such as small irritation, long residence
time in the corneal surface, which can enhance the bioavail-
ability of drugs, and can be used as gels or emulsions matrix.
Lehr et al [19] investigated that PCP had the ability of
improving ocular penetration of gentamicin in the pigmented
rabbit. They designed two gentamicin formulations contain-
ing PCP (neutralized versus non-neutralized) group and saline
control group, and they were dropped into the rabbit eyes
respectively. After analysing the concentrations of gentamicin
in the different tissues of the eyes including cornea, bulbar
conjunctiva, anterior sclera, aqueous humour and vitreous
humour, which were measured by fluorescence polarization
immunoassay, they got the conclusion that both formulations
containing PCP increased the uptake of gentamicin by con-
junctiva two times. Considering only approximately 50%e60%
of the drug was released from the molecular in vitro experi-
ment, therefore the promoting effect was very significant. But
only the drug in the non-neutralized polymers formulation
penetrated into the aqueous humour was observed, the au-
thors believed that the penetration enhancement was prob-
ably caused by its low pH, because it was consistent with the
fact that mucoadhesive performance of poly(acrylic acid) was
achieved under conditions when its carboxyl groups were not
or only partly dissociated, such as at pH < 4.5 [20].Their study
concluded that the biological adhesivity of PCP played amajor
role in helping permeation of the drug at pH < 4.5, and when
themolecules turn into a gel under the pH> 4.5, the increased
viscosity would play a leading role. It means whether PCP was
neutral or not, it was certain of the effect of extending resi-
dence time of drugs in the lesion sites and making their
bioavailability improvement in comparisonwith conventional
eye drops.
Sensoy et al [21] prepared bioadhesive sulfacetamide so-
dium (SA) microspheres using mixture of polymers such as
PCP, hydroxypropylmethyl-cellulose (HPMC) and pectin at
different ratios, and made the microspheres by spray drying
method. The particle size and distribution, thermal behaviour,
morphological characteristics, encapsulation efficiency,
mucoadhesion and drug release studies in vitro have been
investigated. After optimization studies, they chose the
formulation of SA-loaded PCP microsphere with the ratio of
polymers:drug as 2:1. They carried out the in vivo studies on
New Zealand male rabbit eyes with keratitis caused by
Staphylococcus aureus and Pseudomonas aeruginosa. The rabbit
eyes treated with PCP microspheres showed prominently lessclinical symptoms than those treated with SA alone. It means
that the bioadhesivemicrosphereswere highly effective in the
treatment of ocular keratitis. This research also confirmed
that PCP had the bioadhesive effect and the function of
improving bioavailability.
Using liposomes as a carrier in ocular administration can
solve many shortcomings of the conventional solution eye
drops. They have the ability to entrap hydrophilic compounds
in their aqueous compartments and to embody hydrophobic
molecules in their lipid bilayers. The potential of liposome
used in ocular delivery has been researched many years, and
got confirmed previously [22]. Nagarsenker et al [23] prepared
cationic and neutral liposomes of tropicamide, and made
neutral liposomes gel by dispersing the neutral liposomes in
PCP simultaneously. After giving them to the rabbit eyes, they
recorded the pupil dilatory effect. Relative mydriatic strength
by curves showed that tmax after the neutral liposomes gel
administration was significantly greater than the aqueous
solution; after the treatment of simple drug gel and neutral
liposomes gel, the AUC was almost the same. It showed
the improvement of AUC because of the increased viscosity of
the formulation rather than liposome-encapsulated drug.
geScintigraphic studies had confirmed the limitation usage of
neutral liposomes in ocular drug delivery because of no
specificity in the cornea.
2.2. In the nasal mucosal drug delivery systems
The nasal mucosa has a relatively large surface area, rich
submucosal blood supply as well as a relatively high mucosal
permeability with a porous endothelial basement membrane,
which is conducive to the absorption of drugs. Meanwhile the
blood from the nose passes directly into the systemic circu-
lation, avoiding first-pass metabolism of the drug, which
achieved more rapid attainment of therapeutic blood levels
with lower doses, quicker onset of pharmacological activity
and fewer side effects [24,25].
However there are a number of factors limiting the intra-
nasal absorption of high-molecular-weight and hydrophilic
drugs, such as mucociliary clearance, enzymatic activity, and
the barriers formed by epithelium and mucus layer to the
nasal absorption. The applications of absorption enhancers,
proteolytic enzyme inhibitors, and suitable dosage formula-
tions, such as mucoadhesive and inhaled delivery systems,
have been investigated to enhance the nasal bioavailability of
drugs [26]. Unfortunately, many traditional absorption en-
hancers, such as surfactants and bile salts, would cause sig-
nificant damage to the nasal mucosa when used at very
effective concentrations, particularly with long-term expo-
sure. Lots of them have been limited in clinical for their irre-
versible damage to the nasal mucosa [27]. Therefore the
bioadhesive preparations applied to nasal administration has
drawn greater attention. In this approach, when the prepa-
rations contact with the mucus layer, the matrix could absorb
water and swell to form a viscous gel, and extend the resi-
dence time of preparations in the absorption site. This kind of
delivery system can protect the drug from enzymatic degra-
dation by nasal secretions, and reduce the mucoliliary clear-
ance rate [28,29]. At the same time the tight junctions between
the epithelial cells are opened due to temporary dehydration
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the absorption of the drug [30].
The bioadhesive polymers PCP have above properties.
Ugwoke et al [31] conducted the bioavailability study in rabbits
of apomorphinemucoadhesive drug delivery system for nasal
administration with Carbopol 971P, PCP and lactose power
respectively. The result showed that the former two tmax and
MRTwere significantly higher than the latter and the AUCwas
equal with subcutaneously value. Park et al [32] made the de-
livery of plasmid DNA successfully by using the thermores-
ponsive polymer, poloxamer in combination with PCP or
polyethylene oxide. They found both the polymers decreased
the gelation temperature of poloxamer, which indicated that
the gelation temperature could be controlled within the tem-
perature range available in the nasal mucosa. The results also
showed that the preparation containing PCP and poloxamer
was the best, leading to a 11-fold increase in DNA absorbed
when compared to the saline group.
Recently thiolated polymers which are a kind of polymers
containing thiol substructures have gained considerable
attention [33e35]. Sarath [36] studied thiolated dendrimer as a
feasible mucoadhesive excipient for the controlled drug de-
livery systems. The thiolated polycarbophil (PCP-Cys) is re-
ported recently as PCP derivative. It is formed by the carboxyl
groups of PCP which have been neutralized with NaOH cova-
lent binding with amino groups of Cys under the activation of
some activator. Grabovac [37] evaluated the adhesion of some
mucoadhesive polymers by adhesion time and total work of
adhesion on porcine small intestinal mucosa. Results of his
study demonstrated that the adhesion of PCP was higher than
PCP-Cys. Lqbal et al [38] has got the same conclusion. A nasal
microparticulate delivery system for human growth hormone
(hGH) had been studied by Leitner et al [8], the systembased on
the PCP-cysteine (PCP-Cys) in combination with the perme-
ation mediator glutathione (GSH). In the experiment, they
prepared three kinds of microparticles, and the composition
of prescriptions were PCP-Cys/GSH/hGH (7.5:1:1.5), PCP/hGH
(8.5:1.5), and mannitol/hGH (8.5:1.5) respectively. The size
distribution of particles was evaluated by using a laser
diffraction particle size analyzer. The release of hGH from
microparticles was determined by fluorescence labeling in
Franz diffusion cells. In vivo studies on rats were also per-
formed comparing the nasal bioavailability achieved by three
prescriptions above. The results showed that PCP-Cys/GSH/
hGH and PCP/hGH microparticles had an equivalent size dis-
tribution, and the two preparations had almost the same
sustained drug release profiles. The nasal administration of
the PCP-Cys/GSH/hGH group resulted in a relative bioavail-
ability of 8.11  2.15%, which means a 3-fold and 3.3-fold
improvement compared to that of PCP/hGH and mannitol/
hGH group, respectively. The study suggests that the PCP-Cys/
GSH/hGH for nasal microparticulate formulation might be a
promising novel tool for the systemic administration.
2.3. In the vaginal mucosa drug delivery systems
Traditional vaginal delivery systems, such as effervescent,
emulsions and others are easy to leak, thus result in shorter
residence time, lower dose and shorter effective time of the
active drug, which are inconvenient to the patients. Thevagina is the best administration site of BDDS. As vaginal
suppository base, PCP is able to overcome the shortcoming of
stranded short time of the site, which was observed in tradi-
tional creams, suppositories and vaginal tablets, and it can
also improve the hydration of the vaginal tissue.
The applications of the technology have achieved encour-
aging results [39]. The Columbia company has developed two
kinds of bioadhesive formulations (Advantage e STM and
Crinone) using PCP and carbomer as adjuncts. The former
formulation is a bioadhesive gel of contraceptive, which takes
the drugs into the cervix and around by using a special dosing
device, and the drug continue releasing the trace effective
spermicide slowly within 24 h, then the contraceptive effect
will be achieved. The later formulation is Crinone, treatment
of infertility, which can ensure the release time of progester-
one no less than 48 h after one vaginal administration [40].
Robinson et al [41] prepared a vaginal adhesion gel containing
PCP that could reserve the drug in the lesion for 3e4 days.
Wang Chengwei et al [42] developed the nonoxynol vaginal
sustained release gel used PCP, Carbopol 971P and glyceryl
behenate, and examined the released results in vitro. The
consequences showed that the preparation could prolong the
contact time, release the effective dose quickly and continue
for 24 h of an effective dose, which reduced the drug dose, the
toxicity and adverse reactions it caused. Milani et al [43]
compared the effects of two formulations on restoration
vaginal pH value. One was a vaginal suppositories containing
PCP, and the other was an ordinary acidic vaginal douche. The
vaginal pH was a key factor in healthy vaginal ecosystem,
when suffering from bacterial vaginosis, an increase in
vaginal pH of patients was commonly observed. The result
showed that PCP vaginal suppositories appeared to reduce
high vaginal pH to physiologic levels for 80 h compared with
acidic vaginal. Therefore, PCP vaginal suppository has a su-
perior efficacy for treatment of bacterial vaginosis by changing
the vaginal pH and extending the contact time in the vaginal
surface.
2.4. In the buccal mucosa drug delivery systems
Due to its relatively small surface area, lower permeability and
relatively short residence time of the drug in mouth, oral
mucosa is not conducive to administration. However, because
of the smooth oral mucosa surface, large number of sub-
mucous capillary aggregated to the internal jugular vein, not
directly to the liver but to the heart, which can avoid the drug
degradation by gastric intestinal juice, first-pass effect of liver
and enzymemetabolism. Therefore, as an administration site,
buccal is very suitable for bioadhesive drug delivery systems
[44e47]. From another perspective, it is necessary for bio-
adhesive systems that mucus layer covering the buccal mu-
cosa. Unfortunately, the mucus layer not only forms a
physical barrier to the permeation of drugs, but also prevents
sustained drug release by its short turnover time. Interest-
ingly, it has been reported that the presence of bioadhesive
polymers on a mucous membrane might alter the turnover of
mucin because of the residence time of mucoadhesives is
usually longer than the reported mucin turnover time [8].
The bioadhesive formulations possess a higher biocom-
patibility, allowing adhesion to the mucosa in the mouth, and
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catabolic pathways, which could reduce irritation or allergic
reactions in the administration sites [48,49].
Robinson et al [50] prepared a trilamellar membrane agent
for the oral cavity with an impermeable support membrane, a
rate-limiting intermediate film and an adhesion film con-
taining PCP. This adhesive film agent used in the human oral
cavity could reserve 15 h at the site of administration, and
even will not be effected by eating and drinking. The study
confirmed that PCP applied in buccal mucosa drug delivery
systems could prolong the residence time in the active site,
and thus enhance the bioavailability of drugs.3. The applications of PCP in oral drug
delivery systems
There is no doubt that oral preparations are the most wide-
spread and popular routes of administration, but they still
present many limitations, such as mucus covering the GI
epithelia, variable range of pH, high turnover rates of mucus,
rapid luminal enzymatic degradation, first-pass metabolism
by hepatic and longer time to achieve therapeutic blood levels,
which are all possible issues with the oral delivery system
[51e53]. The idea of bioadhesion arose from the need of
localizing the drug at a certain site in the GI tract. Therefore,
the primary objective of bioadhesive systems orally is to
achieve the substantial increase in residence time and once-
daily dosing [54]. The hydrophilic macromolecules are usu-
ally used in the development of mucoadhesive controlled
release formulations, which contain a large amount of
hydrogen bonding groups [55].
3.1. In the controlled release drug delivery systems
Robinson et al [1] studied the bioadhesive properties of a series
of polymers and reported that the preparation containing
chlorothiazide and PCP could sustained release for 8 h after
administered orally to rats. Leung et al [56] showed that PCP
gel provided a gastric retention system. The phenomenonwas
dependent on its viscosity, whichwas produced by swelling in
the stomach. They studied the gastric emptying of the canine
stomach by using a duodenal cannulation technique.
Different concentration of PCP were administered orally to
fasted canines, and it was found that the higher of the PCP’s
concentration, the longer lag time of the gastric emptying. The
conclusion was that PCP increased gastric retention via its
apparent viscosity. Ch’ng et al [57] found that the residence
time of PCP labelled with 51Cr in the rabbit stomach was 17 h,
while the normal control group without the polymer was only
8 h. Carelli et al [58] elaborated a drug release mechanism of
silicone microspheres containing nicotinamide (NAM) and
PCP. In this system, NAM and PCP at the ratio of 1:4 were
dispersed in silicone as the osmotically active particles, and
the silicone was encapsulated in microspheres. When the
osmotically active hydrogel granules swell in the dissolution
medium, the drug dissolved and diffused in the swollen
granules rather than silicone elastomers. In gastric juice (pH
1e2), the swelling degreewas low, and themechanism of drug
release was the dissolutionediffusion. When the pH valueincreased in intestinal juice (pHw7), the swelling degree was
increased significantly, which made the contact surface
among the adjacent particles augment, thus resulted in the
apparent diffusion coefficient of the drug in the matrix
increased. In conclusion, the change of the gel swelling degree
was very beneficial to delaying the drug release in the
gastrointestinal tract. And in some cases, the control release
kinetics was close to a pseudo-zero order. In summary, PCP
with its unique physical characteristics has a great advantage
on the controlled release drug delivery systems.
3.2. In the oral protein and peptide drug delivery
systems
In recent years, with the rapid development of biotechnology,
especially in the progress of the recombinant protein tech-
nology, the therapeutic effects of the peptides and proteins
have received a great concern [59e61]. But the applications
have great limitations for their poor stability, short half-life
in vivo, difficultly penetrating the biofilms and low bioavail-
ability characteristics [62]. The common approach to solve
above problems is to incorporate enzyme inhibitors in the
delivery systems. Since most peptide drugs are large mole-
cules and easily degradated by the proteasomes, therefore
they require the absorption enhancers and protease inhibitors
to overcome GI epithelial barriers [63e66]. At the same time,
different carriers have also been studied, which are used to
shuttle the peptide to the most optimal absorption sites or
tissues of the gut, such as gastrointestinal patch systems
[67e70] and bioadhesive systems for oral drug delivery.
A large amount of work has shown that polyacrylic acid
materials have superior protection capability for protein and
peptide drugs. Luessen et al [71] researched PCP and Carbopol
934 in vitro with the peptide probe 9-desglycinamide, 8-
arginine vasopressin (DGAVP), and reported that both the
two polymers possessed the properties of enhancing absorp-
tion. Moreover, PCP and Carbopol 934 were able to protect
DGAVP free from mucosal homogenate degradation [72] and
inhibit the activity of trypsin [73]. Bai et al [74] had verified that
PCP had the proteolysis inhibition characteristic, which was
found to be effective in aqueous suspensions.
PCP-Cys is also used for oral protein and peptide drug de-
livery systems, because it has some permeation-enhancing
effects. The mechanisms of permeation-enhancing effects:
(1) Reducing the concentration of extracellular calcium by
binding action and opening the tight junctions between cells;
(2) The activities of the protein tyrosine phosphatase in the
cell membrane (e.g. PTP1B) may reduce the tight junctions
opening. While the Cys in PCP-Cys could form a disulfide
bonding with PTP1B, which would inhibit the activities of
PTP1B and thus increase the penetration of the drug by
opening close joints. In vitro experiments showed that PCP-Cys
significantly increased sodium fluorescein, bacitracin FITC
and insulin FITC intestinal epithelial absorption [75].
Martien et al [76] developed and evaluated an oral oligo-
nucleotide (ODN) delivery system based on PCP-Cys/
glutathione (GSH). They made the permeation studies with
PCP-Cys/GSH versus control on Caco-2 cell and rat intestinal
mucosa in vitro. As shown in Fig. 3A and B, apparent perme-
ability increased by 8 times (Caco-2) and 10 times (intestinal
Fig. 3 e Cumulative transport of ODN across Caco-2 cell monolayers and rat intestinal mucosa [76].
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tem might be a promising tool for the oral administration of
proteins or peptides, because it can protect the enzymatic
degradation and promote drugs transport across intestinal
membrane.
Vetter et al [77] designed a highly efficient small intestinal
targeted drug delivery system for fondaparinux based on PCP-
Cys and GSH combined with sodium decanoate. In the pres-
ence of PCP-Cys/GSH/sodium decanoate, the uptake of fon-
daparinux from the intestinal mucosa was 4.1-fold improved,
the AUC in rat plasma from 0 to 24 h was 1.3-fold improved,
and the absolute bioavailability was 6.2-fold improved
compared with the ordinary tablets. This system showed
strong potential of improving the bioavailability of oral drug.4. The applications of PCP in transdermal
delivery systems
Transdermal drug delivery has become a very attractive
alternative to subcutaneous delivery as the skin has the
largest area. It provides good compliance of patients and
controls release characteristics of drugs, and avoids drug
degradation from the GIT or first-pass liver effect. The skin
can also provide a painless interface for systemic adminis-
tration [78,79]. Except some remarkable advantages, skin
administration could also form an extremely effective barrier
to foreign molecules, especially large hydrophilic molecules.
The low permeability of the skin was caused mainly by the
stratum corneum at the outermost layer of the skin [80].
Therefore, a new method is badly needed to overcome the
skin permeability barriers. There are some conventional
techniques that weaken the obstacle with skin absorption
enhancers, such as ultrasound, iontophoresis and micro-
needles [66,81e83]. It is a new method of biological adhesive
system applied in transdermal delivery system, which can
prolong the contact time greatly by adhesion effect and
doesn’t produce discomfort. Some adhesive materials which
fixed with the skin stratum corneum could promote the
permeability of skin by chemical bonding.
Valenta C et al [84] evaluated the possible usages of PCP-Cys
as polymeric matrix for transdermal progesterone applica-
tion. They compared the adhesive characteristics of PCP-Cys
with two control formulations, polyvinylpyrrolidone/HPMC(PVP/HPMC) and polyvinylpyrrolidone/polyvinylalcohol (PVP/
PVA). They analysed the progesterone content by HPLC and
studied the emancipation and the percutaneous permeability
through the in vitro permeation experiment, with full thick-
ness skin of miniature pig as the model in modified Franz
diffusion cells. It indicated that films based on PCP-Cys dis-
played higher cohesive properties than the control group due
to the formation of interchain disulfide bonds. In addition,
the progesterone permeation experiment showed that drug
permeation from PCP-Cys was also higher compared with
PVP/HPMC and PVP/PVA within 24 h. In the last, they got the
conclusion that PCP-Cys might be a novel matrix for trans-
dermal progesterone delivery system with its excellent
adhesiveness.5. Problems and prospects
As a bioadhesive matrix, PCP has the capability of adhering to
the mucus gel layer or mucosal epithelial surfaces, extending
the residence time in some specific sites, such as the admin-
istration sites, the lesion sites and the sites of absorption,
improving the treatment of local or systemic diseases. In vitro
and in vivo experiments havemade remarkable achievements.
However, the results of researching in human body are still
unsatisfactory, which are mainly manifested in the following
aspects.
(1) The update of the mucus layer in vivo is one of the
important reasons for adhesion failure in vivo of bio-
adhesive formulations containing PCP. Meanwhile, the
formulations are also likely to damage mucous or mucous
membranes, and may stimulate the synthesis, secretion
and update of mucus, thus affect the adhesion behaviour
in vivo.
(2) For gastrointestinal bioadhesive drugs, polymers being
hydrated excessively before adhering to the target tissue is
another reason of decreasing their biological adhesivity. At
the same time, the food and feces in gastrointestinal tract
also affect adhesion to the surface of the mucus layer.
(3) Further research in irritation and toxicity of PCP on
mucosal is badly needed.
(4) The evaluation methods in vitro and in vivo of this kind of
preparations need to be further perfected.
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polymer science, life sciences and pharmacy, the use of the
new formulation technologies will overcome the existing de-
ficiencies in certain extent. The bioadhesive formulations will
also tend to be more mature and perfect under the develop-
ment of new multi-functional bioadhesive materials and
specific adhesion materials. In the future, the leading direc-
tion of BDDS is likely to be the bioadhesive microspheres and
specific biological adhesion ligands or coated nanoparticles,
used as sustained release and specific site of administration
[85]. Especially in the bioadhesive particulate drug delivery
system containing PCP, the administration system has
important significance in improving the poor absorption, un-
stable drug (peptide, protein and vaccine) in vivo. With refer-
ence to the theories of mucoadhesion mentioned in the
introduction, various polymer structures and functional
groups can have an effect on the interaction of polymer/
mucus. Thus, modification or control of such polymer struc-
tures may achieve specific mucoadhesive delivery systems.
We may design and synthesise the modified PCP with smaller
molecular structure, lower toxicity and immunogenicity. In
short, by taking PCP or its modifications as the carrier, the
bioadhesive drug delivery system will show great superiority
in reducing the adverse reaction, improving the curative effect
and the compliance of patients.
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